WSG TP-II trial: survival outcomes of de-escalated treatments in HER2+ breast cancer

Dr Nanda on Treatment De-Escalation in HER2+ Breast Cancer and TNBCПодробнее

Role of HER2 expression and pCR in predicting early outcomes in HER2-positive breast cancerПодробнее

Treatment de-escalation and escalation strategies in HER2-positive breast cancerПодробнее

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE...Подробнее

Treatment de-escalation in premenopausal patients with HR+/HER2- breast cancer and micro-metastasisПодробнее

TILs as a prognostic biomarker for treatment de-escalation in HER2-positive breast cancerПодробнее

De-escalation and escalation strategies for HER2+ breast cancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastasesПодробнее

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in...Подробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. GradisharПодробнее

Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockadeПодробнее

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemoПодробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

Leveraging Targeted Therapies to Improve Outcomes Across the Continuum of HER2+ Breast CancerПодробнее

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 InhibitorsПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

ADAPT: de-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel in HR-/HER2+ eBCПодробнее